Monte Rosa Therapeutic (GLUE) TD Cowen 46th Annual Health Care Conference summary

Company overview and platform

• Focuses on molecular glue degraders to target undruggable proteins across multiple disease areas, including oncology, immunology & inflammation (I&I), and cardiovascular conditions.

• Three programs have entered the clinic, all showing positive clinical data, with multiple phase II trials planned for this year.

• Strong financial position, with over $300 million in collaboration revenue and recent financing, supporting robust execution.

• Proprietary QuEEN platform underpins pipeline development and expansion into new targets.

Key clinical programs and data highlights

• MRT-8102 (NEK7 degrader) demonstrated an 85% reduction in CRP and 94% normalization in obese individuals with elevated CRP, outperforming NLRP3 inhibitors and matching IL-6 antibodies.

• Safety profile for MRT-8102 is strong, with no toxicity concerns in phase I and high-dose animal studies.

• GFORCE-1 study (phase IIa) is enrolling three dose levels to optimize dosing and inform phase II selection.

• Lead oncology program targets GSPT1, showing 100% PSA response in AR-mutated prostate cancer patients, with tumor shrinkage observed.

Pipeline progress and future plans

• Multiple phase II trials are set to initiate in 2024, including for NEK7 (GFORCE-1 and GFORCE-2) and GSPT1 (MODIFIER-1).

• Second-generation molecules and additional targets are advancing toward IND submissions by year-end.

• VAV1 program, partnered with Novartis, will enter phase II in multiple indications, leveraging its unique immune modulation profile.